Enveric Biosciences (NASDAQ: ENVB) has announced its decision to solicit Requests-for-Proposal (RFPs) for licensing or selling its PsyAI™ trademark portfolio. The portfolio, managed by its subsidiary Enveric Biosciences Canada, Inc., is no longer strategic as the company sharpens its focus on EB-003, a neuroplastogen designed to promote neuroplasticity without hallucinations.
CEO Joseph Tucker highlighted the PsyAI™ mark’s potential in AI-driven healthcare solutions, valued at $757 billion globally by 2025. He stated the RFP process could optimize asset value while the company advances EB-003 for neuropsychiatric treatments. Submissions remain open until August 31, 2025, with decisions to follow shortly after.
